<code id='9504816254'></code><style id='9504816254'></style>
    • <acronym id='9504816254'></acronym>
      <center id='9504816254'><center id='9504816254'><tfoot id='9504816254'></tfoot></center><abbr id='9504816254'><dir id='9504816254'><tfoot id='9504816254'></tfoot><noframes id='9504816254'>

    • <optgroup id='9504816254'><strike id='9504816254'><sup id='9504816254'></sup></strike><code id='9504816254'></code></optgroup>
        1. <b id='9504816254'><label id='9504816254'><select id='9504816254'><dt id='9504816254'><span id='9504816254'></span></dt></select></label></b><u id='9504816254'></u>
          <i id='9504816254'><strike id='9504816254'><tt id='9504816254'><pre id='9504816254'></pre></tt></strike></i>

          Home / explore / leisure time

          leisure time


          leisure time

          author:leisure time    Page View:23472
          Adam's take main illustration
          Molly Ferguson/STAT

          This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

          The next ALS data readout — overdue but important

          A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

          advertisement

          In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In